KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Non-Current Assets: 2011-2024

Historic Non-Current Assets for Supernus Pharmaceuticals (SUPN) over the last 14 years, with Dec 2024 value amounting to $682.0 million.

  • Supernus Pharmaceuticals' Non-Current Assets rose 17.53% to $825.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $825.9 million, marking a year-over-year increase of 17.53%. This contributed to the annual value of $682.0 million for FY2024, which is 13.07% down from last year.
  • Per Supernus Pharmaceuticals' latest filing, its Non-Current Assets stood at $682.0 million for FY2024, which was down 13.07% from $784.6 million recorded in FY2023.
  • Over the past 5 years, Supernus Pharmaceuticals' Non-Current Assets peaked at $1.1 billion during FY2021, and registered a low of $682.0 million during FY2024.
  • For the 3-year period, Supernus Pharmaceuticals' Non-Current Assets averaged around $811.6 million, with its median value being $784.6 million (2023).
  • In the last 5 years, Supernus Pharmaceuticals' Non-Current Assets rose by 27.06% in 2020 and then decreased by 18.98% in 2023.
  • Over the past 5 years, Supernus Pharmaceuticals' Non-Current Assets (Yearly) stood at $873.7 million in 2020, then climbed by 24.48% to $1.1 billion in 2021, then declined by 10.96% to $968.4 million in 2022, then fell by 18.98% to $784.6 million in 2023, then declined by 13.07% to $682.0 million in 2024.